AI Machine Learning–Based Diabetes Prediction in Older Adults in South Korea: Cross-Sectional Analysis DOI Creative Commons
Hocheol Lee, Myung-Bae Park, Young‐Joo Won

et al.

JMIR Formative Research, Journal Year: 2025, Volume and Issue: 9, P. e57874 - e57874

Published: Jan. 21, 2025

Abstract Background Diabetes is prevalent in older adults, and machine learning algorithms could help predict diabetes this population. Objective This study determined risk factors among adults aged ≥60 years using selected an optimized prediction model. Methods cross-sectional was conducted on 3084 Seoul from January to November 2023. Data were collected a mobile app (Gosufit) that measured depression, stress, anxiety, basal metabolic rate, oxygen saturation, heart average daily step count. Health coordinators recorded data diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease, percent body fat, muscle. The presence of the target variable, with various health indicators as predictors. Machine algorithms, including random forest, gradient boosting model, light extreme k-nearest neighbors, employed for analysis. dataset split into 70% training 30% testing sets. Model performance evaluated accuracy, precision, recall, F1 score, area under curve (AUC). Shapley additive explanations (SHAPs) used model interpretability. Results Significant predictors included hypertension ( χ ² 1 =197.294; P <.001), hyperlipidemia =47.671; age (mean: group 72.66 vs nondiabetes 71.81 years), stress 42.68 41.47; t 3082 =−2.858; =.004), rate 75.05 beats/min 73.14 beats/min; =−7.948; <.001). (XGBM) demonstrated best performance, accuracy 84.88%, precision 77.92%, recall 66.91%, score 72.00, AUC 0.7957. SHAP analysis top-performing XGBM revealed key diabetes: age, saturation. Hypertension strongly increased risk, while advanced elevated levels also showed significant associations. Hyperlipidemia higher rates further heightened probability. These results highlight importance directional impact specific features predicting providing valuable insights stratification targeted interventions. Conclusions focused modifiable factors, crucial establishing system automated collection information lifelog digital devices at service facilities.

Language: Английский

Diagnosis and Management of Prediabetes DOI
Justin B. Echouffo‐Tcheugui, Leigh Perreault, Linong Ji

et al.

JAMA, Journal Year: 2023, Volume and Issue: 329(14), P. 1206 - 1206

Published: April 11, 2023

Importance Prediabetes, an intermediate stage between normal glucose regulation and diabetes, affects 1 in 3 adults the US approximately 720 million individuals worldwide. Observations Prediabetes is defined by a fasting level of 100 to 125 mg/dL, 140 199 mg/dL measured 2 hours after 75-g oral load, or glycated hemoglobin (HbA 1C ) 5.7% 6.4% 6.0% 6.4%. In US, 10% people with prediabetes progress having diabetes each year. A meta-analysis found that at baseline was associated increased mortality cardiovascular event rates (excess absolute risk, 7.36 per 10 000 person-years for 8.75 disease during 6.6 years). Intensive lifestyle modification, consisting calorie restriction, physical activity (≥150 min/wk), self-monitoring, motivational support, decreased incidence 6.2 cases 3-year period. Metformin risk among 3.2 years. most effective women prior gestational younger than 60 years body mass index 35 greater, plasma 110 higher, HbA 1c higher. Conclusions Relevance events, mortality. First-line therapy modification includes weight loss exercise metformin. Lifestyle larger benefit

Language: Английский

Citations

219
3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda

et al.

Diabetes Care, Journal Year: 2022, Volume and Issue: 46(Supplement_1), P. S41 - S48

Published: Dec. 12, 2022

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating Standards annually, or more frequently as warranted. For detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

146
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2024 DOI Open Access
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 47(Supplement_1), P. S43 - S51

Published: Dec. 11, 2023

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

79
Medicare Part D Coverage of Antiobesity Medications — Challenges and Uncertainty Ahead DOI

Khrysta Baig,

Stacie B. Dusetzina, David D. Kim

et al.

New England Journal of Medicine, Journal Year: 2023, Volume and Issue: 388(11), P. 961 - 963

Published: March 11, 2023

Interview with Dr. Ashley Leech on the potential implications of Medicare Part D covering medications for obesity treatment. (11:22)Download could soon be compelled to cover antiobesity medications, which intensifies need address questions effectiveness and cost among its beneficiaries.

Language: Английский

Citations

49
Prediabetes Increases the Risk of Frailty in Prefrail Older Adults With Hypertension: Beneficial Effects of Metformin DOI

Gaetano Santulli,

Valeria Visco, Fahimeh Varzideh

et al.

Hypertension, Journal Year: 2024, Volume and Issue: 81(7), P. 1637 - 1643

Published: May 16, 2024

Prediabetes has garnered increasing attention due to its association with cardiovascular conditions, especially hypertension, which heightens the risk of prefrailty and frailty among older individuals.

Language: Английский

Citations

36
Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum DOI Creative Commons
Michael C. Honigberg, Seyedeh M. Zekavat, James P. Pirruccello

et al.

Journal of the American College of Cardiology, Journal Year: 2021, Volume and Issue: 78(5), P. 453 - 464

Published: May 17, 2021

Language: Английский

Citations

67
Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes DOI Creative Commons
João Sérgio Neves, Connie B. Newman, John Bostrom

et al.

Diabetes Research and Clinical Practice, Journal Year: 2022, Volume and Issue: 190, P. 109980 - 109980

Published: July 3, 2022

Prediabetes affects at least 1 in 3 adults the U.S. and 5 Europe. Although guidelines advocate aggressive management of lipid parameters diabetes, most do not address treatment dyslipidemia prediabetes despite increased atherosclerotic cardiovascular disease (ASCVD) risk. Several criteria are used to diagnose prediabetes: impaired fasting glucose (IFG), tolerance (IGT) HbA1c 5.7–6.4%. Individuals with have a greater risk higher prevalence more atherogenic profile an ASCVD. In addition calculating ASCVD using traditional methods, OGTT may further stratify Those 1-hour plasma ≥8.6 mmol/L (155 mg/dL) and/or 2-hour ≥7.8 (140 Diet lifestyle modification fundamental prediabetes. Statins, ezetimibe PCSK9 inhibitors recommended people requiring pharmacotherapy. high-intensity statins increase this is acceptable because reduction The LDL-C goal should be individualized. those IGT elevated glucose, same intensive approach as for diabetes considered, particularly if other factors present.

Language: Английский

Citations

47
Carotenoids in Drug Discovery and Medicine: Pathways and Molecular Targets Implicated in Human Diseases DOI Creative Commons
Damilohun Samuel Metibemu, Ifedayo Victor Ogungbe

Molecules, Journal Year: 2022, Volume and Issue: 27(18), P. 6005 - 6005

Published: Sept. 15, 2022

Carotenoids are isoprenoid-derived natural products produced in plants, algae, fungi, and photosynthetic bacteria. Most animals cannot synthesize carotenoids because the biosynthetic machinery to create de novo is absent animals, except arthropods. biosynthesized from two C20 geranylgeranyl pyrophosphate (GGPP) molecules made isopentenyl (IPP) dimethylallyl (DMAPP) via methylerythritol 4-phosphate (MEP) route. can be extracted by a variety of methods, including maceration, Soxhlet extraction, supercritical fluid extraction (SFE), microwave-assisted (MAE), accelerated solvent (ASE), ultrasound-assisted (UAE), pulsed electric field (PEF)-assisted enzyme-assisted (EAE). have been reported exert various biochemical actions, inhibition Akt/mTOR, Bcl-2, SAPK/JNK, JAK/STAT, MAPK, Nrf2/Keap1, NF-κB signaling pathways ability increase cholesterol efflux HDL. absorbed intestine. A handful carotenoid-based compounds clinical trials, while some currently used as medicines. The application metabolic engineering techniques for carotenoid production, whole-genome sequencing, use plants cell factories produce specialty presents promising future research. In this review, we discussed biosynthesis carotenoids, roles human health, metabolism source drugs supplements.

Language: Английский

Citations

46
Predicting and preventing heart failure in type 2 diabetes DOI
Ambarish Pandey, Muhammad Shahzeb Khan,

Kershaw V. Patel

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2023, Volume and Issue: 11(8), P. 607 - 624

Published: June 26, 2023

Language: Английский

Citations

37
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2025 DOI
Nuha A. ElSayed, Rozalina G. McCoy, Grazia Aleppo

et al.

Diabetes Care, Journal Year: 2024, Volume and Issue: 48(Supplement_1), P. S50 - S58

Published: Dec. 9, 2024

The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.

Language: Английский

Citations

15